JP2017534257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534257A5 JP2017534257A5 JP2017513786A JP2017513786A JP2017534257A5 JP 2017534257 A5 JP2017534257 A5 JP 2017534257A5 JP 2017513786 A JP2017513786 A JP 2017513786A JP 2017513786 A JP2017513786 A JP 2017513786A JP 2017534257 A5 JP2017534257 A5 JP 2017534257A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- disease
- variant
- sequence
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 54
- 201000010099 disease Diseases 0.000 claims 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 36
- 238000000034 method Methods 0.000 claims 34
- 230000002163 immunogen Effects 0.000 claims 26
- 102000043129 MHC class I family Human genes 0.000 claims 17
- 108091054437 MHC class I family Proteins 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108091026890 Coding region Proteins 0.000 claims 12
- 230000005847 immunogenicity Effects 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 238000004949 mass spectrometry Methods 0.000 claims 6
- 239000013074 reference sample Substances 0.000 claims 5
- 101800001442 Peptide pr Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 3
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 claims 2
- 108010066345 MHC binding peptide Proteins 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000001114 immunoprecipitation Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048742P | 2014-09-10 | 2014-09-10 | |
| US62/048,742 | 2014-09-10 | ||
| PCT/US2015/049491 WO2016040682A1 (en) | 2014-09-10 | 2015-09-10 | Immunogenic mutant peptide screening platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020182268A Division JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534257A JP2017534257A (ja) | 2017-11-24 |
| JP2017534257A5 true JP2017534257A5 (https=) | 2018-10-25 |
| JP7044551B2 JP7044551B2 (ja) | 2022-03-30 |
Family
ID=54238541
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513786A Active JP7044551B2 (ja) | 2014-09-10 | 2015-09-10 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2020182268A Active JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2022178874A Active JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2024112292A Pending JP2024156702A (ja) | 2014-09-10 | 2024-07-12 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020182268A Active JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2022178874A Active JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2024112292A Pending JP2024156702A (ja) | 2014-09-10 | 2024-07-12 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10564165B2 (https=) |
| EP (2) | EP3194970B1 (https=) |
| JP (4) | JP7044551B2 (https=) |
| CN (2) | CN113791220A (https=) |
| AU (3) | AU2015315005B9 (https=) |
| CA (1) | CA2960834A1 (https=) |
| WO (1) | WO2016040682A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| EP3194970B1 (en) | 2014-09-10 | 2021-07-28 | F. Hoffmann-La Roche AG | Immunogenic mutant peptide screening platform |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| CA3056212A1 (en) | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| US11927591B2 (en) | 2016-08-02 | 2024-03-12 | Georgetown University | Methods of identifying novel proteins and antigens in cancer cells |
| US10350280B2 (en) | 2016-08-31 | 2019-07-16 | Medgenome Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
| JP7155470B2 (ja) * | 2017-03-31 | 2022-10-19 | エーシーティー ジェノミックス （アイピー） カンパニー リミテッド | 免疫原性がん特異的エピトープのためのランク付けシステム |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| EP3645028B1 (en) * | 2017-06-27 | 2025-07-09 | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | Mhc-1 genotype restricts the oncogenic mutational landscape |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| KR20260039788A (ko) | 2017-10-10 | 2026-03-20 | 시애틀 프로젝트 코포레이션 | 핫스팟을 이용한 신생항원 동정 |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| CN119851752A (zh) * | 2018-02-27 | 2025-04-18 | 磨石生物公司 | 利用泛等位基因模型进行的新抗原鉴别 |
| US20210020270A1 (en) * | 2018-03-08 | 2021-01-21 | The Trustees Of Indiana University | Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry |
| WO2019183882A1 (zh) * | 2018-03-29 | 2019-10-03 | 深圳达闼科技控股有限公司 | 物质检测方法、装置、电子设备及计算机可读存储介质 |
| EP3807320A4 (en) * | 2018-06-12 | 2022-03-23 | BioNTech US Inc. | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS |
| CA3106562A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| WO2020022899A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| EP3837271A4 (en) * | 2018-08-14 | 2022-06-15 | Board of Regents, The University of Texas System | SINGLE MOLECULE SEQUENCING PEPTIDES BOUND TO THE MAIN HISTOCOMPATIBILITY COMPLEX |
| WO2020101037A1 (ja) * | 2018-11-16 | 2020-05-22 | 株式会社Ｔｎｐパートナーズ | オーダーメイド医療基幹システム |
| CA3115017C (en) | 2018-11-21 | 2023-10-31 | Nec Corporation | Method and system of targeting epitopes for neoantigen-based immunotherapy |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| CN112769742B (zh) * | 2019-11-06 | 2024-06-14 | 电科云(北京)科技有限公司 | Spdz系列协议中的消息验证方法、装置及存储介质 |
| CN111863130A (zh) * | 2020-04-07 | 2020-10-30 | 至本医疗科技（上海）有限公司 | 肿瘤免疫治疗预后标志物的筛选方法及应用 |
| WO2025101535A1 (en) * | 2023-11-07 | 2025-05-15 | Seer, Inc. | Biomolecule cleanup methods, kits, and systems |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US47404A (en) | 1865-04-25 | Improvement in sawing-machines | ||
| US1100474A (en) | 1914-04-01 | 1914-06-16 | Alfred J Croft | Hand-tool. |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| BR9707125A (pt) * | 1996-01-11 | 1999-07-20 | Corixa Corp | Composições e processos para o tratamento e diagnóstico de câncer de mama |
| WO1999024566A1 (en) | 1997-11-06 | 1999-05-20 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
| WO2000020029A1 (en) | 1998-10-05 | 2000-04-13 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| AU1657501A (en) * | 1999-11-12 | 2001-06-06 | Regents Of The University Of California, The | Determining the functions and interactions of proteins by comparative analysis |
| WO2001047959A2 (en) | 1999-11-30 | 2001-07-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050221350A1 (en) | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| EP1512014B1 (en) | 2002-06-13 | 2009-08-05 | MERCK PATENT GmbH | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| CA2651796A1 (en) | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| CA2879024A1 (en) | 2012-07-12 | 2014-01-16 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
| CN118750591A (zh) | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
| WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
| EP3194970B1 (en) | 2014-09-10 | 2021-07-28 | F. Hoffmann-La Roche AG | Immunogenic mutant peptide screening platform |
| WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
-
2015
- 2015-09-10 EP EP15772084.8A patent/EP3194970B1/en active Active
- 2015-09-10 US US14/850,864 patent/US10564165B2/en active Active
- 2015-09-10 AU AU2015315005A patent/AU2015315005B9/en active Active
- 2015-09-10 JP JP2017513786A patent/JP7044551B2/ja active Active
- 2015-09-10 CN CN202110939479.5A patent/CN113791220A/zh active Pending
- 2015-09-10 WO PCT/US2015/049491 patent/WO2016040682A1/en not_active Ceased
- 2015-09-10 EP EP21187832.7A patent/EP3998481A1/en active Pending
- 2015-09-10 CA CA2960834A patent/CA2960834A1/en active Pending
- 2015-09-10 CN CN201580059468.0A patent/CN107076762B/zh active Active
-
2020
- 2020-01-03 US US16/733,988 patent/US12372533B2/en active Active
- 2020-10-30 JP JP2020182268A patent/JP7175951B2/ja active Active
-
2021
- 2021-10-13 AU AU2021250887A patent/AU2021250887B2/en active Active
-
2022
- 2022-11-08 JP JP2022178874A patent/JP7592060B2/ja active Active
-
2024
- 2024-07-02 US US18/762,502 patent/US20240418731A1/en active Pending
- 2024-07-12 JP JP2024112292A patent/JP2024156702A/ja active Pending
-
2025
- 2025-04-14 AU AU2025202619A patent/AU2025202619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534257A5 (https=) | ||
| JP7592060B2 (ja) | 免疫原性変異体ペプチドスクリーニングプラットフォーム | |
| JP2024156702A5 (https=) | ||
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| Bozzacco et al. | Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells | |
| IL300841A (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy | |
| IL268917B2 (en) | A population-based immunogenic peptide identification platform | |
| JP2011523550A5 (https=) | ||
| JP2017525336A5 (https=) | ||
| Gong et al. | Glycyrrhizic acid inhibits myeloid differentiation of hematopoietic stem cells by binding S100 calcium binding protein A8 to improve cognition in aged mice | |
| CN111315401A (zh) | 细菌疫苗 | |
| JP2021502110A5 (https=) | ||
| CN120265313A (zh) | 产生一个或多个衍生自替代翻译控制的共有癌症表位的方法 | |
| CN113272419A (zh) | 制备治疗性t淋巴细胞的方法 | |
| Chen et al. | ECM29/proteasome-mediated self-antigen generation by CNS-resident neuroglia promotes regulatory T cell activation | |
| HK40074082A (en) | Immunogenic mutant peptide screening platform | |
| Guo | Multi-omics Analysis Uncovers Split Formation and Keratinocyte Detachment as Key Drivers of Long-lasting Cellular Effects in Pemphigus Vulgaris | |
| MDC | EFIS y | |
| Ni et al. | Intra-tumoral injection of caerin 1.1 and 1.9 peptides in vaccinated TC-1 tumour bearing mice with PD-1 blockade modulates macrophage heterogeneity and the activation of CD8+ T cells in the tumour microenvironment | |
| CN121762841A (zh) | 一种肿瘤共享细胞膜抗原表位肽及其筛选方法 | |
| WO2021046616A1 (en) | Methods of identifying mhc-bound peptides | |
| HK1242779B (zh) | 免疫原性突变体肽筛选平台 | |
| Luo et al. | FOXP3+ Treg Cells and Systems Biology Approaches to Studying Their Function | |
| JPWO2020227233A5 (https=) | ||
| NZ742911A (en) | Peptide microarrays and novel biomarkers for celiac disease |